Unichem outlines manufacturing plan for generic Hyzaar

By Gareth Macdonald

- Last updated on GMT

iStock/AVNphotolab
iStock/AVNphotolab

Related tags Active pharmaceutical ingredients Hypertension

Unichem Laboratories Limited has confirmed it will make its generic version of Hyzaar for the US market at three plants in India.

The Mumbai-headquartered firm said it will make the active pharmaceutical ingredients (API) - losartan potassium and hydrochlorothiazide – at its facilities in Pithampur, Madhya Pradesh and Roha, Maharashtra.

Unichem also confirmed in a Bombay Stock Exchange (BSE) filing​ that it will make the finished formulation of the drug – which is a version of Merck & Co’s blood pressure pill - at its manufacturing facility in Ghaziabad, Uttar Pradesh.

The US Food and Drug Administration (FDA) approved Unichem’s version of the drug earlier this week.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us

Products

View more

Webinars